Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction... ...

Jeremiah Buckley getting some news on Fizer this morning. For that, we're going to turn to Angelica Peoples. Hey, Angelica. >> Hey, Carl.Well, Fizer saying that one of its drugs for cickle cell disease has failed a phase three trial. Now, this is um you their hopes weren't particularly high for the cickle cell portfolio. But this is still important for Fizer because if you remember a few years ago, they spent about five billion dollars to acquire a company called Global Blood Therapeutics.And the deal has a ...